When life-and-death decisions are at stake, will patients welcome AI to their care team? As part of ILCN’s series on AI in lung cancer, patient advocate Angus Pratt explores issues of trust, safety, accuracy, and more. Read more
Dr. Quincy Chu recently shared results from the phase III IND227 trial, which also demonstrated improved progression-free survival in mesothelioma patients who received the combination compared to those who received standard chemotherapy alone. Read more
In stage II-IIIA NSCLC patients with high PD-L1 expression, the benefits of atezolizumab and platinum-based chemotherapy after surgical resection appeared to be most prominent in the lobectomy subgroup according to Dr. Alessandro Brunelli and colleagues. Read more
Editor-in-Chief Dr. Alex Adjei announced the journal’s impact factor once again rose in 2022 and says it remains the leading journal in thoracic oncology. Read more
Like it or not, AI will be part the diagnostic and therapeutic landscape, and it is incumbent on clinicians to understand its implications, limitations, and benefits, ILCN editors say. Read more
Investigator Ticiana Leal, MD, said the the phase III LUNAR study met its primary endpoint and demonstrated a statistically significant 3-month improvement in median overall survival versus the standard of care. Read more
Dr. Sharyn Katz and colleagues summarize key recommendations for improving imaging quality in malignant pleural mesothelioma. Read more
The newly elected board members, including President-Elect Dr. Caicun Zhou, will assume their roles at the upcoming 2023 World Conference on Lung Cancer in Singapore. Read more
Canada to require health warnings on cigarettes. US FDA approves application for pemetrexed injection, grants priority review for repotrectinib. Read more
Dr. Roy Herbst said the results reinforce adjuvant osimertinib as the standard of care for patients with resected, EGFR-mutated stage IB-IIIA non-small cell lung cancer and highlight the importance of early biomarker testing. Read more